Literature DB >> 19710669

The as-yet unfulfilled promise of p38 MAPK inhibitors.

Susan E Sweeney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19710669     DOI： 10.1038/nrrheum.2009.171

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.

Authors:  Changhai Ding
Journal:  Curr Opin Investig Drugs       Date:  2006-11

Review 2.  Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

Authors:  M Hegen; J C Keith; M Collins; C L Nickerson-Nutter
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

Review 3.  The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.

Authors:  G Schett; J Zwerina; G Firestein
Journal:  Ann Rheum Dis       Date:  2007-09-07       Impact factor: 19.103

4.  Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

Authors:  Stanley B Cohen; Tien-Tsai Cheng; Vishala Chindalore; Nemanja Damjanov; Ruben Burgos-Vargas; Patricia Delora; Kathleen Zimany; Helen Travers; John P Caulfield
Journal:  Arthritis Rheum       Date:  2009-02

5.  Rheumatoid arthritis in a mouse?

Authors:  Gary S Firestein
Journal:  Nat Clin Pract Rheumatol       Date:  2009-01

6.  Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

Authors:  Nemanja Damjanov; Robert S Kauffman; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2009-05

7.  Is spleen tyrosine kinase inhibition an effective therapy for patients with RA?

Authors:  Axel J Hueber; Iain B McInnes
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03

8.  Inhibition of p38: has the fat lady sung?

Authors:  Mark C Genovese
Journal:  Arthritis Rheum       Date:  2009-02

9.  Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.

Authors:  David L Boyle; Toni L Jones; Deepa Hammaker; Camille I Svensson; Sanna Rosengren; Salvatore Albani; Linda Sorkin; Gary S Firestein
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling.

Authors:  Lore M Gruenbaum; Racheline Schwartz; Joseph R Woska; Rodney P DeLeon; Gregory W Peet; Thomas C Warren; Alison Capolino; Lisa Mara; Maurice M Morelock; Anthony Shrutkowski; Jessi Wildeson Jones; Christopher A Pargellis
Journal:  Biochem Pharmacol       Date:  2008-11-05       Impact factor: 5.858
  10 in total
  11 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes.

Authors:  H Joos; W Albrecht; S Laufer; R E Brenner
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Role of p38 inhibition in cardiac ischemia/reperfusion injury.

Authors:  Sarawut Kumphune; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

4.  Tissue-Specific Regulation of p38α-Mediated Inflammation in Con A-Induced Acute Liver Damage.

Authors:  Young Jun Kang; Bo-Ram Bang; Motoyuki Otsuka; Kinya Otsu
Journal:  J Immunol       Date:  2015-04-17       Impact factor: 5.422

5.  The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look.

Authors:  Andrew R Clark; Jonathan LE Dean
Journal:  Open Rheumatol J       Date:  2012-09-07

Review 6.  The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis.

Authors:  Athanasios Mavropoulos; Eirini I Rigopoulou; Christos Liaskos; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  Clin Dev Immunol       Date:  2013-09-12

7.  Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6.

Authors:  Deepa Hammaker; David L Boyle; Katharyn Topolewski; Gary S Firestein
Journal:  J Inflamm (Lond)       Date:  2014-05-16       Impact factor: 4.981

8.  Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

Authors:  S De Buck; W Hueber; A Vitaliti; F Straube; C Emotte; G Bruin; R Woessner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-09

9.  Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts.

Authors:  Weili Hui; Chenqi Zhao; Sylvain G Bourgoin
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

10.  p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity.

Authors:  Athanasios Mavropoulos; Timoklia Orfanidou; Christos Liaskos; Daniel S Smyk; Vassiliki Spyrou; Lazaros I Sakkas; Eirini I Rigopoulou; Dimitrios P Bogdanos
Journal:  Autoimmune Dis       Date:  2013-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.